Top

Published in:

01-06-2005 | Review Article

European Technology Platform on Innovative Medicines

Authors: Dr Fergal Donnelly, Philippe Jehenson

Published in: Pharmaceutical Medicine | Issue 3/2005

Abstract

The European pharmaceutical industry is seriously lagging behind its competitors, mainly in the US, and seems to be particularly slow in harnessing the benefits of the revolution in biotechnology, as evidenced by the growing numbers of biotechnology corporations on the far side of the Atlantic as well as the movement of infrastructure and personnel from Europe across the Atlantic to better opportunities that are unavailable in Europe.

The Technology Platform for Innovative Medicines for European citizens is proposed as an integral part of the European Commission proposals for the Seventh Framework Programme (2007–2013) and aims to redress this imbalance. It is aimed at enhancing and accelerating the development process of medicines, including those derived from biotechnology, so as to ensure the most rapid application of scientific breakthroughs into approved new medicines. This will be achieved by stimulating integrated forms of co-operation in research and development, in particular through reinforced public-private partnerships, with a view to providing the European population with early access to new, more targeted medicines, while at the same time, strengthening the European science base and fostering economic growth in the pharmaceutical and biotechnology industries.

This includes classical pharmaceutical but not new and emerging technologies, such as biotechnology, which are dealt with separately.

This term is used interchangeably with metabolomics.

Gambardella A, Orsenigo L, Pammolli F. Global competitiveness in pharmaceuticals: a European perspective [online]. Report Prepared for the Directorate-General Enterprise of the European Commission. Brussels: Enterprise Directorate-General, 2000 Nov: 6. Available from URL:http://europa.eu.int/comm/enterprise/library/enterprise-papers/pdf/enterprise_paper_01_2001.pdf [Accessed 2005 Aug 15]

EFPIA. The pharmaceutical industry in figures: key data -2005 update [online]. Brussels: EFPIA, 2005. Available from URL:http://www.efpia.org/6_publ/infigures2005.pdf [Accessed 2005 Aug 15]

IMS World Review 2003 [online]. Available from URL:http://www.imshealth.com/ims/portal/front/articleC/0,2777,6599_3665_41336931,00.html [Accessed 2005 Aug 15]

Contract Pharma. July/August 2005, top pharma companies [online]. Available from URL:http://www.contractpharma.com/top_comp.php [Accessed 2005 Aug 15]

G10 Medicines. High level group on innovation and provision of medicines: consultation paper (November 2001). Annex — Powerpoint presentation [online]. Available from URL:http://www.efpia.org/4_pos/economic/g10Annex.pdf [Accessed 2005 Sep 6]

High Level Group on Innovation and Provision of Medicines: recommendations for Action (G10 Medicines — Report) [online]. 7 May 2002. Brussels: European Communities, 2002. Available from URL:http://europa.eu.int/comm/health/ph_overview/Documents/key08_en.pdf [Accessed 2005 Aug 15]

Communication from the Commission to the Council, the European Parliament, the Economic and Social Committee and the Committee of the Regions. A stronger European-based pharmaceutical industry for the benefit of the patient: a call for action. Brussels, 1 July 2003. COM (2003) 383 final [online]. Available from URL:http://europa.eu.int/eur-lex/pri/en/dpi/cnc/doc/2003/com2003_0383en01.doc [Accessed 2005 Aug 15]

Communication from the Commission to the Council, the European Parliament, the Economic and Social Committee and the Committee of the Regions. Life sciences and biotechnology: a strategy for Europe. Brussels, 3 October 2001. COM (2002) 27 final [online]. Available from URL:http://europa.eu.int/comm/biotechnology/pdf/ecworkshopsreports_en.pdf [Accessed 2005 Aug 15]

Commission of the European Communities. Science and technology, the key to Europe’s future: guidelines for future European Union policy to support research. Brussels, 16.6.2004 COM (2004) 353 final [online]. Available from URL:http://europa.eu.int/eur-lex/en/com/cnc/2004/com2004_0353en01.pdf [Accessed 2005 Aug 15]

10.

Decision No. 1513/2002/EC of the European Parliament and of the Council of 27 June 2002 concerning the Sixth Framework Programme of the European Community for research, technological development and demonstration activities, contributing to the creation of the European Research Area and to Innovation (2002 to 2006) [online]. Available from URL:http://europa.eu.int/eurlex/pri/en/oj/dat/2002/l_232/l_23220020829en00010033.pdf [Accessed 2005 Aug 15]

11.

Commission Staff Working Document. Report on European Technology Platforms and Joint Technology Initiatives: fostering public-private R&D partnerships to boost Europe’s industrial competitiveness. Brussels, 10.6.2005, SEC (2005) 800

12.

Proposal for a Decision of the European Parliament and of the Council concerning the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013). Brussels, 6 April 2005. COM (2005) 119 final [online]. Available from URL:http://www.bit.ac.at/7RP/doks/com-fp7-proposals_en.pdf [Accessed 2005 Aug 15]

13.

Technology platforms: from definition to implementation of a common research agenda [online]. Luxembourg: Office for Official Publications of the European Communities, 2004: 88. Available from URL:http://www.eurogif.org/wimages/Technology_Platforms_21_September_2004.pdf [Accessed 2005 Aug 15]

14.

European Council. Presidency conclusions. Lisbon European Council: 23–24 March 2000 [online]. Available from URL:http://www.bologna-berlin2003.de/pdf/PRESIDENCY_CONCLUSIONS_Lissabon.pdf [Accessed 2005 Sep 6]

15.

Communication from the Commission: investing in research: an action plan for Europe. Brussels, 20 April 2003. COM (2003) 226 final [online]. Available from URL:http://europa.eu.int/comm/research/era/3pct/pdf/action-plan.pdf [Accessed 2005 Aug 15]

16.

DiMasi JA, Hansen RW, Grabowski HG, The price of innovation: new estimates of drug development costs. J Health Econ 2003; 22 (2): 151–185PubMedCrossRef

17.

The CMR International 2004 R&D factbook. Epsom: Centre for Medicines Research International Ltd, 2004 [CMR04-234R]

18.

European Agency for the Evaluation of Medicinal Products. Position paper on terminology in pharmacogenetics. London, 21 November 2002. EMEA/CPMP/3070/01 [online]. Available from URL:http://www.emea.eu.int/pdfs/human/press/pp/307001en.pdf [Accessed 2005 Aug 15]

19.

Hamadeh HK, Afshari CA. Toxicogenomics: principles and applications. New York: John Wiley & Sons, Inc., 2004CrossRef

20.

Tomer KB, Merrick DB. Toxicoproteomics: a parallel approach to identifying biomarkers. Environ Health Perspect 2003 Aug; 111 (11): A578–9PubMedCrossRef

21.

Nicholson JK, Lindon JC, Holmes E. ‘Metabonomics’: understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 1999; 29: 1181–9PubMedCrossRef

22.

Nicholson JK, Connelly J, Lindon JC, et al. Metabonomics: a platform for studying drug toxicity and gene function. Nat Rev Drug Discov 2002; 1: 153–61PubMedCrossRef

23.

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharm Ther 2001 Mar; 69 (3): unnumbered

24.

European Commission-DG Enterprise and Industry. Review of pharmaceutical legislation [online]. Available from URL:http://pharmacos.eudra.org/F2/review/index.htm [Accessed 2005 Aug 15]

25.

European Platform on Innovative Medicines [online]. Available from URL:http://europa.eu.int/comm/research/fp6/index_en.cfm?p=1_innomed [Accessed 2005 Sep 19]

26.

Gilbert J, Henske P, Singh A. Rebuilding big pharma’s business model. In: In vivo: the business & medicine report [2003; 21 (10)]. Norwalk (CT): Windhover Information Inc., 2003

Title: European Technology Platform on Innovative Medicines
Authors: Dr Fergal Donnelly
Philippe Jehenson
Publication date: 01-06-2005
Publisher: Springer International Publishing
Published in: Pharmaceutical Medicine / Issue 3/2005
Print ISSN: 1178-2595
Electronic ISSN: 1179-1993
DOI: https://doi.org/10.2165/00124363-200519030-00003

Keynote webinar | Spotlight on medication adherence

Springer Medicine

European Technology Platform on Innovative Medicines

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2005

Postmarketing Surveillance

Society of Pharmaceutical Medicine

American Thoracic Society

Summary of Recent Deal Activity

Major Pharmaceutical Conferences

The US Food and Drug Administration and Emergency Contraception